Your trusted source for investing success

Tag: therapeutics

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
Telferscot Shareholders Approve Transactions

Telferscot Shareholders Approve Transactions

Telferscot Resources Inc. (CSE: TFS) (“Telferscot” or the “Company”) is pleased to announce that the Company’s shareholders have overwhelmingly approved the Plan of Arrangement and the Amalgamation Agreement facilitating the takeover of Canntab Therapeutics Limited (previously announced on January 15, March 1, 2018).

Amicus Therapeutics Announces Approval of Galafold® (Migalastat) for Fabry Disease in Japan

Amicus Therapeutics (Nasdaq:FOLD) announced today that Japan’s Ministry of Health, Labour and Welfare has approved the oral small molecule pharmacological chaperone Galafold capsules 123mg (migalastat) for treatment of patients aged 16 years and older with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) and who have an amenable mutation.

As quoted in the

Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with CellBridge

Precision Therapeutics (NASDAQ:AIPT) formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis has secured a license agreement with CellBridge Incorporated which grants it access to CellBridge’s 3D biomimetic support technology. This follows the Company’s recently announced license agreements with SyntArray and 48Hour Discovery and is the latest milestone in the Company’s strategy to

Trillium Therapeutics’ TTI-621 Receives Orphan Drug Designation for the Treatment of Cutaneous T-Cell Lymphoma

Trillium Therapeutics (Nasdaq:TRIL) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted an Orphan Drug Designation to TTI-621 for the treatment of cutaneous T-cell lymphoma.

As quoted in the press release:
“The FDA’s decision to

aTyr Pharma Announces Fourth Quarter and Year-End 2017 Operating Results

aTyr Pharma (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced operating results for the fourth quarter and year ended December 31, 2017.

As quoted in the press release:
“We achieved several key milestones in 2017 that will enable the continued

AIT Therapeutics Reports Year End 2017 Financial Results

AIT Therapeutics (OTC:AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced financial results for the fourth quarter and year ended December 31, 2017.

As quoted in the press

Aclaris Therapeutics Announces Positive Update on Phase 2 Results after a 3-month Follow-Up

Aclaris Therapeutics (NASDAQ:ACRS) announced positive results from the 3-month, post-treatment, follow-up evaluation period of its twice-weekly placebo-controlled trial (WART-203) of A-101 45% topical solution (A-101 45%), an investigational new drug consisting of a proprietary high-concentration hydrogen peroxide topical solution being developed as a prescription treatment for common warts (verruca vulgaris).


Knight Announces Exclusive License Agreement with Ardelyx for Tenapanor

Knight Therapeutics (TSX:GUD) announced today a license agreement with Ardelyx (NASDAQ:ARDX) that provides Knight with exclusive rights to commercialize tenapanor in Canada. Tenapanor is Ardelyx’s oral, first-in-class small molecule treatment that has completed Phase 3 development for irritable bowel syndrome with constipation (IBS-C) and is being evaluated in a second

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
Enter Your Log In Credentials
This setting should only be used on your home or work computer.


Privacy & Legal Policy

Privacy Policy

Investing News Network

Send this to a friend

I thought you might find this interesting:
Telferscot Shareholders Approve Transactions